MiR-4674 regulates angiogenesis in tissue injury by targeting p38K signaling in endothelial cells.


Journal

American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225

Informations de publication

Date de publication:
01 03 2020
Historique:
pubmed: 9 1 2020
medline: 31 7 2020
entrez: 9 1 2020
Statut: ppublish

Résumé

Neoangiogenesis is critical for tissue repair in response to injury such as myocardial ischemia or dermal wound healing. MicroRNAs are small noncoding RNAs and important regulators of angiogenesis under physiological and pathological disease states. Therefore, identification of microRNAs that may restore impaired angiogenesis in response to tissue injury may provide new targets for therapy. Using a microRNA microarray profiling approach, we identified a human-specific microRNA, miR-4674, that was significantly decreased in patients after myocardial tissue injury and had an endothelial cell (EC)-enriched expression pattern. Functionally, overexpression of miR-4674 markedly attenuated EC proliferation, migration, network tube formation, and spheroid sprouting, whereas blockade of miR-4674 had the opposite effects. Transcriptomic profiling, gene set enrichment analyses, bioinformatics, 3'-untranslated region (3'-UTR) reporter and microribonucleoprotein immunoprecipitation (miRNP-IP) assays, and small interfering RNA dependency studies revealed that miR-4674 regulates VEGF stimulated-p38 mitogen-activated protein kinase (MAPK) signaling and targets interleukin 1 receptor-associated kinase 1 (Irak1) and BICD cargo adaptor 2 (Bicd2) in ECs. Furthermore, Irak1 and Bicd2 were necessary for miR-4674-driven EC proliferation and migration. Finally, neutralization of miR-4674 increased angiogenesis, Irak1 and Bicd2 expression, and p38 phosphorylation in human skin organoids as a model of tissue injury. Collectively, targeting miR-4674 may provide a novel therapeutic target for tissue repair in pathological disease states associated with impaired angiogenesis.

Identifiants

pubmed: 31913696
doi: 10.1152/ajpcell.00542.2019
pmc: PMC7099516
doi:

Substances chimiques

MIRN4674 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

C524-C535

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States

Références

Stem Cell Res. 2017 Apr;20:94-104
pubmed: 28340487
Clin Sci (Lond). 2002 Feb;102(2):187-94
pubmed: 11834138
Curr Opin Cardiol. 2007 Sep;22(5):458-63
pubmed: 17762548
Cancer Cell. 2010 Aug 9;18(2):171-84
pubmed: 20708158
J Biol Chem. 2008 Jun 6;283(23):15878-83
pubmed: 18417479
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
JCI Insight. 2017 Mar 9;2(5):e90651
pubmed: 28289712
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):193-200
pubmed: 23325476
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1458-1474
pubmed: 31092013
Dev Cell. 2008 Aug;15(2):272-84
pubmed: 18694566
Eur J Pharmacol. 2018 Jan 5;818:124-131
pubmed: 29037767
Trans Am Clin Climatol Assoc. 2016;127:224-234
pubmed: 28066055
Theranostics. 2012;2(8):801-14
pubmed: 22916079
Diabetes Care. 2011 May;34 Suppl 2:S285-90
pubmed: 21525470
EMBO Mol Med. 2014 Jul 25;6(9):1105-20
pubmed: 25063693
Circ Res. 2013 Nov 8;113(11):1231-41
pubmed: 24047927
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Lancet. 2011 Jun 4;377(9781):1929-37
pubmed: 21621834
Diabetes Care. 2007 Jun;30(6):1351-6
pubmed: 17337492
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8287-92
pubmed: 21536891
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Circ Res. 2007 Oct 26;101(9):948-56
pubmed: 17823371
Am J Physiol Renal Physiol. 2005 May;288(5):F871-80
pubmed: 15821252
JACC Basic Transl Sci. 2017 Oct;2(5):503-512
pubmed: 29430558
Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2729-36
pubmed: 17308014
FASEB J. 2019 Apr;33(4):5599-5614
pubmed: 30668922
Clin Cardiol. 2004 May;27(5):281-6
pubmed: 15188944
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2595-606
pubmed: 21885851
J Am Coll Cardiol. 2008 Jul 29;52(5):387-93
pubmed: 18652948
J Cell Biol. 2002 Jan 7;156(1):149-60
pubmed: 11781339
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):870-879
pubmed: 29449333
J Mol Cell Cardiol. 2016 Feb;91:151-9
pubmed: 26776318
Lancet. 2002 Jul 6;360(9326):23-33
pubmed: 12114037
Curr Vasc Pharmacol. 2012 Jan;10(1):77-93
pubmed: 22112349
Lancet. 1999 Aug 7;354(9177):447-55
pubmed: 10465168
J Biol Chem. 2002 Mar 8;277(10):8048-53
pubmed: 11777917
Vascul Pharmacol. 2006 Nov;45(5):334-9
pubmed: 17008132
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006502
pubmed: 22762016
J Biol Chem. 2004 Nov 26;279(48):50446-54
pubmed: 15371454
J Surg Res. 2014 Jul;190(1):358-66
pubmed: 24814764
J Am Coll Cardiol. 2005 Sep 6;46(5):835-7
pubmed: 16139133
J Clin Invest. 2012 Jun;122(6):1973-90
pubmed: 22622040
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
Hum Gene Ther. 2006 Jun;17(6):683-91
pubmed: 16776576
Lancet. 2000 Jan 22;355(9200):253-9
pubmed: 10675071
Circ Res. 2014 Jan 3;114(1):32-40
pubmed: 24084690
Science. 2009 Jun 26;324(5935):1710-3
pubmed: 19460962
J Am Coll Cardiol. 2000 Mar 15;35(4):968-73
pubmed: 10732896
PLoS One. 2013 May 28;8(5):e64434
pubmed: 23724047
Ageing Res Rev. 2009 Oct;8(4):306-13
pubmed: 19389489
Trends Cardiovasc Med. 2002 Apr;12(3):108-14
pubmed: 12007735
Cold Spring Harb Perspect Med. 2013 Feb 01;3(2):a006643
pubmed: 23169571
Angiogenesis. 2018 Nov;21(4):699-710
pubmed: 29956018
FASEB J. 2016 Sep;30(9):3216-26
pubmed: 27297585

Auteurs

Basak Icli (B)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Hao Li (H)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Daniel Pérez-Cremades (D)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Physiology, University of Valencia and Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Biomedical Research Institute, Valencia, Spain.

Winona Wu (W)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Denizhan Ozdemir (D)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Medical Biology, Hacettepe University, Ankara, Turkey.

Stefan Haemmig (S)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Raphael Boesch Guimaraes (RB)

Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, Rio Grande do Sul, Brazil.

Andre Manica (A)

Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, Rio Grande do Sul, Brazil.

Julio F Marchini (JF)

Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.

Dennis P Orgill (DP)

Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Mark W Feinberg (MW)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH